Servier in licensing pact with SIMM for the development in China of lucitanib

Servier has signed an agreement with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, (SIMM)  for the development in China of lucitanib, a promising targeted anti-tumor drug with antiangiogenic effects. The drug has demonstrated impressive efficacy in PhI/PhII trials in metastatic breast cancer patients. 

Neurodyn acquires all assets related to Galantos preclinical asset Memogain - A prodrug of Galantamine intended for the treatment of Alzheimer

Neurodyn Inc. has acquired from Galantos Pharma GmbH, Mainz, Germany (galantos.com) all assets related to their Alzheimer’s prescription drug candidate – Memogain®. Memogain®  is a prodrug of Galantamine and has completed an extensive preclinical development program and is ready to proceed into Phase 1 clinical trials in late 2013.  The pro-drug greatly enhances delivery of galantamine to the brain and is expected to offer decisive advantages over drugs currently available for AD that are limited by very modest improvements in cognition, adverse effects which limit adherence, and no significant disease modification. The expected medical benefits of Memogain® include significantly greater effectiveness as a cognition enhancer and absence of dose-limiting gastro-intestinal side effects. 

Avanir and OptiNose agree to collaborate on Development and Commercialization for a New Fast-Acting Investigational Product for the Treatment of Acute Migraine

Avanir Pharmaceuticals, Inc. and OptiNose AS today announced that the companies have entered into an exclusive North American license agreement for the development and commercialization of OptiNose's novel Breath Powered™ intranasal delivery system containing low-dose sumatriptan powder to treat acute migraine. If approved, this product would be the first and only fast-acting, dry-powder nasal delivery form of sumatriptan

Moberg outlicenses China rights for Kerasal Nail to Menarini

Sweden based Moberg Pharma AB (OMX: MOB) has granted to  Menarini Asia-Pacific, a member of the Menarini Group – a top 40 global pharmaceutical company –  the exclusive rights to market and sell Kerasal Nail™ in China. The companies now intend to seek marketing authorization for the product in the Chinese market.

Amgen inlicenses US rights for CHF drug from Servier

AMGN announced a deal with Servier (a privately held French pharma) to gain US rights to  Procoralan. Procoralan is an oral drug indicated for treatment of chronic heart failure and stable angina (chest pain). Amgen will pay $50mn upfront payment and future undisclosed milestones and royalties. 

Vivus partners its Erectile dysfunction compound with Menarini

Vivus has partnered its Erectile dysfunction compound SPEDRA (STENDRA in the U.S.) with private company Menarini for marketing in 40 European countries and Australia and New Zealand. Vivus would get up to ~$102 million in milestones plus undisclosed royalties. Menarini would pay $21m in upfront payment.

 The deal would provide meaningful cash to Vivus for funding a quicker Qsymia launch. 

Enter your email address: Delivered by FeedBurner

International Medica Foundation outlicenses China rights to its neonatal rotavirus vaccine to Shanghai BravoBio

The International Medica Foundation has outlicensed to Shanghai BravoBio Co., Ltd. of China,  rights to Rotashield -  the first rotavirus vaccine that has been clinically tested for use in newborns. Shanghai BravoBio will be responsible for developing the vaccine in China.  

Rotashield has several attributes, which makes it the ideal rotavirus vaccine, of which the important ones being

Ambrx and Zhejiang Medicine Co. Ltd. (ZMC) collaborate for development of Ambrx HER2+ve breast cancer compound

US based Ambrx which specializes in protein therapeutics has entered into a collaboration with China based Zhejiang Medicine Co. Ltd. (ZMC) for the development and commercialization of  ARX788 which is Ambrx's most advanced internally developed site specific antibody drug conjugate (ADC) targeting Her2-positive breast cancer.

Bristol-Myers collaboarate with Simcere Pharmaceuticals for development and commercialization of subcutaneous formulation of Bristol-Myer Squibb's RA drug Orencia

BMY and Simcere pharmaceuticals have agreed to collaborate in China on the development and commercialization of the subcutaneous (SC) formulation of Bristol-Myers Squibb's biologic medicine, Orencia® (abatacept), for the treatment of rheumatoid arthritis. Orencia SC is already on the market for the treatment of rheumatoid arthritis in the U.S., Europe and Japan.

Genor Biopharma and BIOCND partner to develop Biosimilar copies of Humira and Herceptin

Genor Biopharma Co. Ltd and BIOCND Inc, a Korean biotech company, have partnered to develop two mAb biosimilars for international markets.  According to the signed agreement, Genor Biopharma licensed out to BIOCND the South Asia, Southeast and Northeast Asia (except Greater China), and Russia right of GB232 (a Adalimumab biosimilar), and ROW (except Greater China, Japan, the United States, and Europe) right of GB221 (a Trastuzumab biosimilar).

BeiGene outlicenses Global development and commercialization rights (ex-China) for its novel BRAF inhibitor to Merck KGAA

BeiGene Co., Ltd.  a biotech R&D company in Beijing, and Merck KGaA, Darmstadt, Germany,  have entered into a global licensing, co-development, and commercialization agreement for BeiGene-283.  BeiGene-283 is is a second-generation BRAF inhibitor for the treatment of cancer developed by BeiGene. BRAF inhibtors so far has been successfully tested in metastatic melanoma. There are two BRAF inhibitors that are already marketed - Dabrafenib (GSK) and Vemurafenib (Roche).
BeiGene-283 is currently in preclinical development and is expected to enter clinical development next year. BRAF inhibitors target a protein (BRAF) that is a downstream component of the MAPK* pathway, which is thought to promote cancer cell growth and is dysregulated in a number of human  cancers.

Scilone pharma inlicenses heart failure drug rights for China from

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) has entered into an agreement with 

Zensun (Shanghai) Science & Technology Co., Ltd. which grants SciClone a license and the

exclusive rights in China , Hong Kong and Macau to promote, market, distribute and sell Neucardin™, a novel, first - in - class therapeutic drug for the treatment of patients with 

intermediate to advanced chronic heart failure.

 

OxOnc Development to partner Pfizer for the development of its NSCLC drug Xalkori in specific NSCLC patients in China

OxOnc Development LP announced that it has entered into a co-development agreement with Pfizer Inc., to conduct a pivotal clinical trial of Pfizer's crizotinib, marketed under the trademark Xalkori(R), for the treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring a ROS1 (c-ros) gene

Lee Pharma Collaborate with Portola for development of new generation anticoagulant Betrixaban in China

Portola Pharmaceuticals, Inc. and Lee’s Pharmaceutical have entered into an agreement to jointly expand the Phase 3 APEX study of betrixaban into China, with an option for Lee’s to negotiate for the commercial rights to the drug in China.